Maravai Lifesciences Holdings, INC Schedule 13G passive stakes

Millennium Management LLC, along with affiliated entities and Israel A. Englander, has filed a Schedule 13G, reporting beneficial ownership of 4.7% of Maravai LifeSciences Holdings, Inc. Class A Common Stock.

12 West Capital Management LP and Joel Ramin have disclosed a beneficial ownership of 4.9% of Maravai LifeSciences Holdings, Inc. Class A Common Stock.

Several entities and individuals have collectively increased their beneficial ownership of Maravai LifeSciences Holdings, Inc. Class A Common Stock to over 9.21%.

Millennium Management LLC and associated entities have filed a Schedule 13G indicating their beneficial ownership of Maravai LifeSciences Holdings, Inc. has fallen below the 5% threshold.

12 West Capital Management LP and Joel Ramin have increased their beneficial ownership in Maravai LifeSciences Holdings, Inc. to 6.2% of Class A Common Stock.

A group of investors, including Stuart Feldman, Matthew Barkoff, and Joshua Wool, along with associated entities, reported a collective beneficial ownership of 7.23% in Maravai LifeSciences Holdings, Inc. Class A Common Stock.

A group of investors, including Stuart Feldman, has disclosed beneficial ownership of 8.33% of Maravai LifeSciences Holdings, Inc.'s Class A Common Stock.

The Vanguard Group has filed an amendment to its Schedule 13G, reporting a 4.92% beneficial ownership in Maravai LifeSciences Holdings Inc.

BlackRock, Inc. has disclosed an increased passive ownership stake of 5.9% in Maravai LifeSciences Holdings, Inc., holding over 8.5 million shares.

The Vanguard Group has filed an amended Schedule 13G, reporting a beneficial ownership of 6.51% in Maravai LifeSciences Holdings Inc.'s common stock as of June 30, 2025.

A group of investors, including Hudson View Holdings LLC, Hudson View Capital LLC, JD Squared Holdings II LLC, JD Squared Capital II LLC, Stuart Feldman, Matthew Barkoff, and Joshua Wool, has disclosed a combined passive beneficial ownership of 6.55% in Maravai LifeSciences Holdings, Inc.

Investment firm 12 West Capital Management LP and Joel Ramin have filed an amended Schedule 13G, reporting a shared beneficial ownership of 8.2% of Maravai LifeSciences Holdings, Inc.'s Class A Common Stock as of December 31, 2024.